Startup Beat

Actipulse Neuroscience, a neuro-tech startup specializing in non-invasive brain therapies, has joined the renowned Y Combinator, granting the company large-scale resources to improve the treatment of Major Depressive Disorder (MDD), tobacco addiction, Alzheimer’s Disease, and Parkinson’s Disease.

The company’s patented neuromodulation devices, pictured above, use magnetic pulses to directly target the root causes of these brain conditions. Although similar FDA-approved therapies already exist, the current complexity and cost of care limits them almost exclusively to a hospital setting. Designed to be used in home, Actipulse’s treatments eliminate these issues, vastly improving accessibility.

The treatment for MDD is currently in its final FDA pivotal phase, and the company hopes to achieve full FDA approval for its in-home treatment within 24 months. Other treatments, including those to slow the progression of Alzheimer’s and Parkinson’s Disease, will begin efficacy trials later this year, and tobacco addiction treatment will begin FDA pivotal trials

To read the full article click on the 'post' link at the top.